Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 4-9 , January 2004

Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

  • Hossein Borghaei

      Affiliations

    • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • *Address reprint requests to Russell J. Schilder, MD, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA 19111
    • 1Dr Borghaei serves as a member of the speakers’ list for DesignWright. Dr Schilder receives research grant support from Bristol-Myers Squibb and is a member of the speakers’ bureau for Biogen Idec Inc, OrthoBiotech, and Genentech.
    • ,
  • Russell J. Schilder

      Affiliations

    • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • 1Dr Borghaei serves as a member of the speakers’ list for DesignWright. Dr Schilder receives research grant support from Bristol-Myers Squibb and is a member of the speakers’ bureau for Biogen Idec Inc, OrthoBiotech, and Genentech.

References 

  1. Cheson BD. Rituximab: Clinical development and future directions. Expert Opin Biol Ther. 2002;2:97–110
  2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  3. Keating M, O’Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 2000;27:86–90
  4. Dillman RO. Radiolabeled anti-CD-20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545–3557
  5. Witzig TE, Emmanouilides C, Molina A, et al.  Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol. 2003;22:597; (abstr 2400)
  6. Knox SJ, Goris ML, Trisler K, et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  7. Witzig TE, White CA, Wiseman GA, et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803
  8. White CA, Halpern SE, Parker BA, et al.  Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 1996;87:3640–3649
  9. Witzig TE, Gordon LI, Cabanillas F, et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  10. Wiseman GA, Gordon LI, Multani PS, et al.  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336–4342
  11. Parker BA, Vassos AB, Halpern SE, et al.  Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res. 1990;50:1022s–1028s
  12. Witzig TE, White CA, Gordon LI, et al.  Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–1270
  13. Witzig TE, Flinn IW, Gordon LI, et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–3269
  14. Zevalin (ibritumomab tiuxetan) prescribing information. San Diego, CA: IDEC Pharmaceuticals,; 2002;
  15. Wagner HN, Wiseman GA, Marcus CS, et al.  Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–272
  16. Emmanouilides CE, Witzig TE, Molina A, et al.  Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol. 2003;22:595; (abstr 2392)
  17. Coiffier B, Lepage E, Briere J, et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  18. Czuczman M, Witzig TE, Gaston I, et al.  Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood. 2002;100:357a; (abstr 1386)
  19. Leone G, Mele L, Pulsoni A, et al.  The incidence of secondary leukemias. Haematologica. 1999;84:937–945
  20. Schilder RJ, Witzig T, Gordon L, et al.  90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol. 2002;21:267a; (abstr 1064)
  21. Ansell SM, Ristow KM, Habermann TM, et al.  Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3885–3890

PII: S0001-2998(03)00079-5

doi: 10.1053/j.semnuclmed.2003.11.002

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 4-9 , January 2004

Article Tools

* Image Usage & Resolution